Phosphodiesterase inhibition overcomes pulmonary vasomotor dysfunction in acute lung injury

Journal of Surgical Research

Volumn 71, Issue 2, 1997, Pages 145-149

  Sheridan, Brett C ^a   McIntyre Jr , Robert C ^a   Meldrum, Daniel R ^a   Fullerton, David A ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMYCIN; CYCLIC GMP; ENDOTOXIN; ISOBUTYLMETHYLXANTHINE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; CATABOLISM; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; LUNG INJURY; LUNG VASOCONSTRICTION; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE RELAXATION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

EID: 0030865287     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5139     Document Type: Article

References (26)

1. Ignarro L. J. Biosynthesis, and metabolism of endothelium-derived nitric oxide. Annu. Rev. Pharmacol. Toxicol. 30:1990;535.
2. Moncada S., Palmer R. M., Higgs J. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:1991;109.
3. Palmer R. M. J., Ferrige A. G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (London). 327:1987;525.
4. Fullerton D. A., McIntyre R. C., Hahn A. R., Agrafojo J., Koike K., Banerjee A., Harken A. H. Dysfunction of cGMP-mediated pulmonary vasorelaxation in endotoxin-induced acute lung injury. Am. J. Physiol. 268:1995;L1029.
5. McIntyre R. C., Banerjee A., Agrafojo J., Fullerton D. A. Pulmonary hypertension in acute lung injury is due to impaired vasodilatation with intact vascular contractility. J. Surg. Res. 58:1995;765.
6. Chang S. W., Feddersen C. O., Henson P. M., Voelkel N. F. Platelet activating factor mediates hemodynamic changes and lung injury in endotoxin treated rats. J. Clin. Invest. 79:1987;1498.
7. Huttemeier P. C., Watkins W. D., Peterson M. B., Zapol W. M. Acute pulmonary hypertension and lung thromboxane release after endotoxin infusion in normal and leukopenic sheep. Circ. Res. 50:1982;688.
8. Meyrick B. O., Brigham K. J. Acute effects ofEscherichia coli. Lab. Invest. 48:1983;458.
9. Li J., Oliver J. R., Lu C., Philips J. B. Delayed thromboxane or tumor necrosis factor-alpha, but not leukotriene inhibition, attenuates prolonged pulmonary hypertension in endotoxemia. Am. J. Med. Sci. 310:1995;103.
10. Gwitner G. H., Knolblauch A., Smith A. L., Sies H., Adkinson N. F. Oxidant- and lipid-induced pulmonary vasoconstriction mediated by arachidonic acid metabolites. J. Appl. Physiol. 55:1983;949.
11. Tate R. M., Vanbenthuysen K. M., Shasby D. M., McMurtry I. F., Repine J. E. Oxygen radical mediated permeability edema and vasoconstriction in isolated perfused rabbit lungs. Am. Rev. Respir. Dis. 126:1982;552.
12. Walkins D. W., Huttemeier P. C., Kong D., Peterson M. B. Thromboxane and pulmonary hypertension followingE. coli. Prostaglandins. 23:1982;273.
13. Braner D. A., Fineman J. R., Chang R., Soifer S. J. M & B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol. 264:1993;H252.
14. Weishaar R. E., Cain M. H., Bristol J. A. A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J. Med. Chem. 28:1985;537.
15. Giembycz M. A., Dent G. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin. Exp. Allergy. 22:1992;337.
16. Rabe K. F., Tenor H., Dent G., Schudt C., Nakashima M., Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am. J. Physiol. 266:1994;L536.
17. Thomas M. K., Francis S. H., Corbin J. D. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J. Biol. Chem. 265:1990;14964.
18. Hussein A., Meyrick B., Graber S., Berry L., Brigham K. L. Attenuation of endotoxin-induced cytotoxicity and prostacyclin production in cultured bovine pulmonary artery endothelial cells by phosphodiesterase inhibition. Exp. Lung Res. 14:1988;637.
19. McIntyre R. C., Harken A. H., Fullerton D. A. Clinical updates: Mechanisms of pulmonary vasomotor control in acute lung injury. Surgery. 115:1994;273.
20. Ziegler J. W., Ivy D. D., Fox J. J., Kinsella J. P., Clarke W. R., Abman S. H. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilatation in the ovine fetus. Am. J. Physiol. 269:1995;H473.
21. Kinsella J. P., Torielli F., Ziegler J. W., Ivy D. D., Abman S. H. Dipyridamole augmentation of response to nitric oxide. Lancet. 346:1995;647.
22. Cohen A. H., Hanson K., Morris K., Fouty B., McMurtry I. F., Clarke W., Rodman D. M. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. 97:1996;172.
23. Hoffman H., Hatherhill J. R., Crowley J., Harada H., Yonemaru M., Zheng H., Ishizaka A., Raffin T. A. Early post-treatment with pentoxifylline or dibutryl cAMP attenuatesEscherichia coli. Am. Rev. Respir. Dis. 143:1991;289.
24. Ishizaka A., Wu Z., Stephens K. E., Harada H., Hogue R. S., O'Hanley P. T., Raffin T. A. Attenuation of acute lung injury in septic guinea pigs by pentoxifylline. Am. Rev. Respir. Dis. 138:1988;376.
25. Wang P., Ba Z. F., Stepp K. J., Chaudry I. H. Pentoxifylline attenuates the depressed endothelial cell function and vascular muscle contractility following trauma and hemorrhagic shock. J. Trauma. 39:1995;121.
26. Zeni F., Pain P., Vindimian M., Gay J., Gery P., Bertrand M., Page Y., Page D., Vermesch R., Bertrand J. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: Results from a double-blind, randomized, placebo-controlled study. Crit. Care Med. 24:1996;207.